The concise review of etiology, pathology, and treatment strategy of polyarteritis nodosa

Takaharu Ikeda

Article ID: 1452
Vol 6, Issue 2, 2022, Article identifier:19-25

VIEWS - 520 (Abstract) 176 (PDF)


Polyarteritis nodosa (PAN) is a necrotizing vasculitis that targets medium-sized muscular arteries and can involve small-sized arteries. The pathogenesis of classic PAN remains unclear, except for secondary PAN or vasculitis that is indistinguishable from PAN due to genetic abnormalities such as deficiency of adenosine deaminase 2. The histopathological characters of PAN change over time from the onset. The type of remission induction therapy to be adopted depends on the disease severity. When it results in remission, corticosteroid dose reduction will begin and will be shifted to remission maintenance therapy.


Polyarteritis Nodosa; Deficiency of Adenosine Deaminase 2; Anti-Phosphatidylserine-Prothrombin Complex Antibod-ies

Full Text:



Davies DJ, Moran JE, Niallnm JF, et al. Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus etiology? British Medical Journal (Clinical Research Ed.) 1982; 285(6342): 606. doi: 10.1136/bmj.285.6342.606

van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. The Lancet 1985; 325(8426): 425–429. doi: 10.1016/S0140-6736(85)91147-X

Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism 2013; 65(1): 1–11. doi: 10.1002/art.37715

Zhou Q, Dan Y, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. The New England Journal of Medicine 2014; 370: 911–920. doi: 10.1056/NEJMoa1307361

Elkan PN, Pierce SB, Segal R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. The New England Journal of Medicine 2014; 370: 921–931. doi: 10.1056/NEJMoa1307362

Barron KS, Aksentijevich I, Deuitch NT, et al. The spectrum of the deficiency of adenosine deaminase 2: An observational analysis of a 60 patient cohort. Frontiers in Immunology 2022; 12: 811473. doi: 10.3389/fimmu.2021.811473

Gibson KM, Morishita KA, Dancey P, et al. Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. Arthritis & Rheumatology 2019; 71(10): 1747–1755. doi: 10.1002/art.40913

Chung SA, Gorelik M, Langford CA, et al. The 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Care & Research 2021; 73(8): 1061–1070. doi: 10.1002/acr.24633

Kawakami T, Yamazaki M, Mizoguchi M, et al. High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. Arthritis Care & Research 2007; 57(8): 1507–1513. doi: 10.1002/art.23081

Okano T, Takeuchi S, Soma Y, et al. Presence of anti-phosphatidylserine-prothrombin complex antibodies and anti-moesin antibodies in patients with polyarteritis nodosa. The Journal of Dermatology 2017; 44(1): 18–22. doi: 10.1111/1346-8138.13491

Kawakami T, Tamura Y, Dong Y, et al. Anti-phosphatidylserine/prothrombin complex antibodies in patients with cutaneous vasculitis: Possible involvement in the pathogenesis. The Journal of Dermatology 2021; 48(5): 703–706. doi: 10.1111/1346-8138.15810

Ikeda T, Furukawa F, Kawakami T, et al. Outline of guidelines for the management of vasculitis and vascular disorders in Japan, 2016 revised edition. The Journal of Dermatology 2018; 45(2): 122–127. doi: 10.1111/1346-8138.14086

Isobe M, Amano K, Arimura Y, et al. JCA 2017 guideline on management of vasculitis syndrome. Circulation Journal 2020; 84(2): 299–359. doi: 10.1253/circj.CJ-19-0773



  • There are currently no refbacks.

Copyright (c) 2022 Takaharu Ikeda

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.